The Biden administration is exploring a proposal to potentially include weight loss medications from pharmaceutical giants Eli Lilly (LLY) and Novo Nordisk (NVO) under Medicare and Medicaid coverage.

Yahoo Finance Health Reporter Anjalee Khemlani explores how the Centers for Medicare & Medicaid Services' (CMS) plans to reinterpret existing statutory language that currently prohibits coverage of these weight-loss drugs.

To watch more expert insights and analysis on the latest market action, check out more Catalysts here.

This post was written by Angel Smith